Hikma Pharmaceuticals USA Inc. announced Friday that the FDA has approved an ANDA for the generic version of meperidine hydrochloride, opening the door for potential additional market entry for the oral opioid pain reliever just as demand for generic alternatives surges. This regulatory milestone signals a strategic move by Hikma to capitalize on the current volatility in the supply of branded meperidine formulations.